The Myositis Association recognizes that the myositis patient’s best hope for a cure lies in research. TMA offers a research fellowship program to attract and encourage post-doctoral trainees (PhD and MD) and young physicians to pursue careers in the field of myositis research. TMA also funds research grants to initiate innovative pilot projects that will…
Continue Reading
Today, Kezar Life Sciences announced topline results from the PRESIDIO study, evaluating the efficacy and safety of zetomipzomib in dermatomyositis and polymyositis. In this study, most patients experienced a clinically meaningful improvement however, zetomipzomib did not demonstrate a significant differentiation from the placebo. We will learn more from this study with additional deeper analysis in…
Continue Reading
The Myositis Association (TMA) is partnering with the University of Pittsburgh for a new NIH-sponsored study entitled, “Myositis Patient Centered Tele-Research ( My-PACER ).” The investigators of this study (Drs. Rohit Aggarwal, Chester V. Oddis and Siamak Moghadam) have a long-standing interest in myositis. Dr. Aggarwal is also vice chair of TMA’s Medical Advisory Board….
Continue Reading
When retired Yale professor of economics Martin Shubik was diagnosed with inclusion body myositis (IBM) in 2003, very little was known about the disease. At the time, few professional resources had answers to simple questions like “What can I expect from this disease?”
Continue Reading
Corbus Pharmaceuticals is testing lenabasum in an exciting phase 3 clinical trial. The trial, known as DETERMINE, is designed to evaluate the efficacy and safety of lenabasum for the treatment of dermatomyositis.
Continue Reading